Delaware’s top court ruled in GSK’s favor in saying it will review the admissibility of expert evidence in an upcoming trial ...

UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...

GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.

British pharmaceutical group GSK on Friday welcomed victory in drawn out US litigation regarding its Zantac drug for heartburn that allegedly caused cancer. The over-the-counter treatment ...

That win closely followed a settlement in a separate Zantac prostate cancer ... personal injury case to go to trial, Chicago jurors in late May absolved GSK and Boehringer Ingelheim of fault ...

Shares in GSK fell around 9% this morning after ... of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial. Judge Vivian Medinilla of Delaware Superior Court issued an ...

Twelve days after GSK secured a key win in Florida ... to take to early trials. On the first track, plaintiffs have retained 10 experts to offer their opinions on whether ranitidine can cause ...

GSK (NYSE:GSK) stock was up 3% in afternoon trading Tuesday in the wake of a ruling by a Delaware court on whether certain ...

GSK Plc got approval from Delaware’s top court Tuesday to quickly appeal a ruling allowing expert testimony at trial over ...

GSK shares jumped ... claims its Zantac heartburn drug causes cancer. The Delaware Supreme Court said it will review a decision by a lower court to let an upcoming trial hear evidence from ...

Zamboni is expected to say the 'Tanner study - which was not submitted to the FDA until 2019 - provides evidence that GSK knew about Zantac's potential health impacts, but failed to make the ...